Novo Nordisk Says Global Payer Pressure Limits Price Rises
This article was originally published in The Pink Sheet Daily
Executive Summary
Recent SWITCH-2 data encourage plans for submitting supplemental indication of reduced hypoglycemia for Tresiba, company suggests; Victoza sales continue growth but below predictions, and "we are losing market to Trulicity."